TKI-31

inhibits angiogenesis by combined suppression signaling pathway of VEGFR2 and PDGFRbeta; structure in first source

Also Known As:

6-(2,6-dichlorophenyl)-2-(3-fluorinphenylamino)-8-methyl-8H-pyrido(2,3-d)pyrimidine-7-one

Networked: 0 relevant articles (0 outcomes, 0 trials/studies)